Small Molecule CISH Inhibitor
Oncology (Solid Tumors)
Key Facts
About Intima Bioscience
Intima Bioscience is pioneering a novel approach to cancer immunotherapy by targeting the intracellular checkpoint protein CISH (Cytokine-Inducible SH2-containing protein), a key negative regulator of T-cell signaling. The company has advanced into clinical trials, with a first-in-human study (NCT04426669) using CRISPR-Cas9 to genetically engineer CISH-knockout tumor-infiltrating lymphocytes (TILs) in patients with metastatic gastrointestinal cancers, with initial data presented in 2025. Beyond cell therapy, Intima is developing a small molecule inhibitor platform against CISH, aiming for an orally available, off-the-shelf therapeutic. Its strategy positions it at the intersection of cutting-edge gene editing and traditional drug discovery to overcome limitations of current checkpoint inhibitors.
View full company profileTherapeutic Areas
Other Oncology (Solid Tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-02 | Molecure | Phase I |
| Athebody® DARPins for Targeted Radioligands (with POINT Biopharma) | Athebio | Pre-clinical |
| AB821 | Asher Biotherapeutics | Preclinical |
| Undisclosed Preclinical Pipeline | OncoResponse | Preclinical |
| Undisclosed Platform Program | Da Zen Theranostics | Pre-clinical |
| Compound42 | Abbmira Therapeutics | Pre-clinical |
| Clinical Decision Support Service | Curematch | Commercial |
| CV6-168 | CV6 Therapeutics | Phase 1a |
| Chemophototherapy (CPT) | POP Biotechnologies | Pre-clinical |
| HRD Testing Solution | SeqOne Genomics | Commercial |
| Platform Validation & Partnership Development | SingleCell Biotechnology | Pre-clinical |
| Undisclosed | Y-Trap | Preclinical |